Purinergic receptors are well accepted as an attractive therapeutic target of age-related cardiovascular diseases (Sunggip et al., 2017), and we suggest the potential benefits of the use of P2Y2R agonists in the prevention of cardiac hypertrophy. The gene discussed is P2RY2; the disease is cardiac hypertrophy.